Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-MUST in Chronic Cholecystitis and Biliary Dyskinesia
NCT06842966Phase 2Recruiting
- Sponsor
- Valenta Pharm
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 4-MUST in chronic cholecystitis and biliary dyskinesia (4 arms), sponsored by Valenta Pharm. Primary endpoint: Average reduction in the severity of pain/discomfort in the upper abdomen on the VAS at Day 29. Started Oct 2024; status: recruiting.
02
Drugs
4-MUST
03
Conditions
chronic cholecystitisbiliary dyskinesia
Beyond the preview
Go deeper on NCT06842966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842966.